Skip to main content
Premium Trial:

Request an Annual Quote

MRC Holland Gets CE-IVD Mark for Spinal Muscular Atrophy Assay

NEW YORK (GenomeWeb) — Dutch biotech firm MRC Holland said recently that it has received CE-IVD marking for its SALSA MC002 assay for spinal muscular atrophy (SMA) screening in newborns. It added it has launched the test.

SMA is a neuromuscular disease caused by mutations in the SMN1 gene. According to MRC Holland, the melt curve analysis-based assay is designed to detect the presence or absence of SMN1 exon 7 in newborns. It does not require DNA purification and can provide results from dried blood spot card punches in around four hours.

MRC Holland noted that the market for SMA screening has increased with the 2016 approval of Biogen Idec's treatment Spinraza (nusinersen), which is administered before symptoms appear.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.